New hope for tough ovarian cancer: phase 3 trial of Mo-Rez drug launches

NCT ID NCT07286266

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 4 times

Summary

This study tests a new drug called mocertatug rezetecan (Mo-Rez) in 450 people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if Mo-Rez helps people live longer without their cancer growing compared to standard treatments. Researchers will also check for side effects and how well the drug is tolerated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinosarcoma clear cell adenocarcinoma endometrial endometrioid adenocarcinoma fallopian tube cancer ovarian cancer ovarian carcinoma ovarian neoplasm primary peritoneal carcinoma serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN NEOPLASMS

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Randwick, New South Wales, 2031, Australia
GSK Investigational Site
RECRUITING

Montreal, Quebec, H2X 0C1, Canada
GSK Investigational Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site
RECRUITING

Hyōgo, 673-8558, Japan
GSK Investigational Site
RECRUITING

Osaka, 569-8686, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.